Romiplostim (Nplate) — CPB 0768 | AETNA Coverage Update

Aetna modified CPB 0768 for romiplostim (Nplate), effective October 29, 2025. Here's what billing teams need to know before submitting claims under HCPCS J2802.

Aetna, a CVS Health company, updated its Aetna romiplostim coverage policy under CPB 0768 Aetna system, expanding covered indications beyond immune thrombocytopenia (ITP) to include myelodysplastic syndromes, chemotherapy-induced thrombocytopenia, hematopoietic syndrome of acute radiation syndrome, and immune checkpoint inhibitor-related thrombocytopenia. The primary billing code is HCPCS J2802 (injection, romiplostim, 1 microgram), administered via CPT 96372, 96374, 96375, 96376, or 96379. If your team bills Nplate for Aetna commercial members, this coverage policy update changes which diagnoses qualify and what platelet thresholds trigger medical necessity.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Romiplostim (Nplate) — CPB 0768
Policy Code	CPB 0768
Change Type	Modified
Effective Date	October 29, 2025
Impact Level	High
Specialties Affected	Hematology, Oncology, Infusion centers, Hospital outpatient
Key Action	Audit active Nplate authorizations against updated platelet thresholds and new covered indications before billing under J2802

---

Aetna Romiplostim Coverage Criteria and Medical Necessity Requirements 2025

The updated coverage policy requires a hematologist or oncologist to prescribe or consult on every Nplate order. No exceptions. If your practice is billing J2802 under a primary care or internal medicine provider without that specialist consultation documented, expect a claim denial.

Aetna now recognizes five distinct indications for romiplostim medical necessity. Each has its own threshold criteria. Treating them as interchangeable will get claims rejected.

Immune Thrombocytopenia (ITP)

This is still the core indication for most billing teams. Aetna requires both of the following for initial approval:

#	Covered Indication Copy
1	The member had an inadequate response or intolerance to prior therapy with corticosteroids, immunoglobulins, or splenectomy.
2	The member had an untransfused platelet count below 30 x 10⁹/L at any point before starting romiplostim — OR a platelet count of 30–50 x 10⁹/L with symptomatic bleeding (significant mucous membrane bleeding, GI bleeding, or trauma) or documented bleeding risk factors.

That second criterion trips up a lot of authorizations. The platelet count threshold is specific: below 30 x 10⁹/L gets automatic consideration. Between 30 and 50 x 10⁹/L requires documented symptomatic bleeding or risk factors. Code D69.3 is your primary ICD-10 for ITP. Make sure your documentation explicitly ties the platelet count to the prior authorization request.

Chemotherapy-Induced Thrombocytopenia (CIT)

This is one of the newer covered indications, and it matters for oncology billing teams. Aetna covers romiplostim under CPB 0768 for CIT when either:

#	Covered Indication Copy
1	The platelet count is below 100 x 10⁹/L for at least three to four weeks after the last chemotherapy administration, or
2	Chemotherapy has been delayed because of thrombocytopenia.

ICD-10 D69.59 is the code to use here. The "delayed chemo" criterion is significant — it gives you a coverage pathway even when the platelet count hasn't hit the hard threshold. Document the delay explicitly in the clinical notes.

Immune Checkpoint Inhibitor-Related Thrombocytopenia

Aetna covers romiplostim for G3 thrombocytopenia (25,000–50,000/mm³) or G4 thrombocytopenia (below 25,000/mm³) related to immune checkpoint inhibitors, but only after corticosteroids failed over one to two weeks. This is a step therapy requirement built into the medical necessity criteria. If you skip documenting the corticosteroid trial, the prior authorization will fail. D69.3 and D69.59 are both mapped to this indication depending on the clinical context.

Myelodysplastic Syndromes and HS-ARS

For MDS (ICD-10 D46.22, D46.9, D46.c), Aetna covers Nplate without the platelet threshold requirements that apply to ITP. The same applies to hematopoietic syndrome of acute radiation syndrome. These are cleaner coverage pathways with less documentation friction — but you still need the hematologist/oncologist prescriber requirement met.

Continuation of Therapy

Continuation criteria are layered and specific. For ITP, Aetna allows continuation when:

That last criterion is critical. Aetna does not automatically cut off coverage when counts normalize. If counts are between 200 and 400 x 10⁹/L, you can still get continuation approved — but you must document the dose adjustment plan. Platelets over 400 x 10⁹/L are where coverage gets complicated, and you should talk to your compliance officer before billing continuation in that range.

---

Aetna Romiplostim Exclusions and Non-Covered Indications

Aetna explicitly excludes romiplostim when used at the same time as other thrombopoietin receptor agonists. That means no concurrent use with:

#	Excluded Procedure Copy
1	Eltrombopag (Promacta, Alvaiz)
2	Avatrombopag (Doptelet) — HCPCS J2355
3	Lusutrombopag (Mulpleta)

Spleen tyrosine kinase inhibitors like fostamatinib (Tavalisse) are also excluded from concurrent use. Concurrent use of romiplostim with another TPO agonist or Tavalisse is a hard policy exclusion. Submit only after confirming the member's medication list is clear of these agents.

All indications not listed in the covered criteria are classified as experimental, investigational, or unproven. Aetna romiplostim reimbursement is not available for off-label use outside the five listed indications.

---

Coverage Indications at a Glance

---

Aetna Romiplostim Billing Guidelines and Action Items 2025

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Romiplostim Under CPB 0768

HCPCS Codes — Romiplostim Billing

Code	Type	Description	Status Copy
J2802	HCPCS	Injection, romiplostim, 1 microgram	Covered when selection criteria are met
J2355	HCPCS	Injection, oprelvekin, 5mg	Related code — concurrent use with J2802 triggers exclusion

CPT Codes — Administration and Related Procedures

Note: The splenectomy codes (38100–38120) appear in this policy as related codes — splenectomy is a prior therapy requirement for ITP eligibility. Coverage determinations for splenectomy procedures are outside the scope of this CPB.

Key ICD-10-CM Diagnosis Codes

The full ICD-10 list in CPB 0768 contains 155 codes. The table above covers the primary diagnosis codes your billing team will use most often. Review the full policy at CPB 0768 on PayerPolicy for the complete list.

---